Homeopaths all over the world are having much success with treating HIV/AIDS, especially in Africa. It is important to note that homeopathy should be used along with, and not instead of, antiretroviral drugs (ARVs).
Aids Remedy Fund Study of Homeopathic Iquilai for the Treatment of AIDS
In a study done in Kenya in 2006, 228 HIV-positive patients underwent homeopathic treatment, and 90% experienced improvement in their condition. Full details of this study can be found here: http://www.aidsremedyfund.org/cms/studies/
Homeopathy for Health in Africa
World-renowned homeopath Jeremy Sherr has treated thousands of HIV/AIDS successfully at his clinic in Tanzania, Africa. “Patients report an increase in energy and well-being and an improvement in the debilitating side effects of anti-retroviral treatment. This means that they can continue taking the ARV drugs for a longer time before the medications lose their effectiveness. They can return to work, feed and take care of their children and send them to school.” For more information about this project, visit http://www.homeopathyforhealthinafrica.org/index.php
Studies and Research on the Homeopathic Treatment of HIV/AIDS
Muraleedharan, K.C., S.K. Dey , Popula Prasad , V.A. Siddiqui ,Rupali Dixit ,Vikram Singh , C. Nayak. “Effectiveness of homoeopathic medicines in HIV patients – A clinical trial.” Indian Journal of Research in Homoeopathy Vol. 4, No. 4, October-December 2010.
Targeted therapy for HIV treatment is the antiretroviral therapy but varied types of drug toxicities and adverse reactions are quiet common. Homoeopathy is popularly known for its unique methods to tackle the infection especially in viral diseases. The study was an open clinical trial using individualized homoeopathic medicines selected through repertorization. The aim of study was to observe the changes in CD4 and Viral load volumes after intervention of individualized homoeopathic medicines. 90 seropositive patients were enrolled in two study centers of Central Council for Research in Homoeopathy (CCRH). 72 patients, who completed the follow up period of six months, were assessed. There was significant change in Viral load volume as compared to the baseline data (95% CI, 0.16, 1.24, p=0.012), but no significant changes was observed in CD4 cells (95% CI, -9.31, 57.84, p=0.154).The other parameters like Body Mass Index (BMI) (95%,-1.12,-.57, p<0.001) showed significant improvement. After homoeopathic intervention, WHO-QOL (Quality of Life) parameters showed statistical significant changes at p<0.05 in physical health, psychological and envirnomental domains but in social domain no significant change was noted.
The diagnoses of all patients in this study were initially confirmed by the two accepted laboratory analyses, ELIZA and the Western Blot, which were performed by a World Health Organization-recognized center in India. After homeopathic treatment, 12 patients who initially tested HIV+ from the ELIZA test were found to be HIV- later. The initial report on this study showed that only 2 of these 12 patients were tested again through the Western Blot, which opened the study up to criticism because the ELIZA test is known to have errors and requires a confirmatory test with the Western Blot. Because of the extremely atypical result of this study, the editor of the homeopathic journal in which it was published was so startled that he wrote an editorial questioning its authenticity. (P. Fisher, “When to Believe the Unbelievable,” British Homoeopathic Journal, January, 1993, 82:2-3.) However, since this editorial, the authors have confirmed that 9 of the original 12 patients tested negative according to the Western Blot, and an additional two people changed from HIV+ to HIV-. (D.P. Rastogi, “Asymptomatic HIV Carriers,” British Homoeopathic Journal, January 1994, 83:54.)
OBJECTIVE: This study was aimed to evaluate the immuno-modulator role of homeopathic remedies in Human Immunodeficiency Virus (HIV) infection.
METHODOLOGY: A randomised double blind clinical trial was conducted to compare the effect of homeopathic remedies with placebo, on CD4+ve T-lymphocytes in HIV infected individuals, conforming to Centres for Disease Control (CDC) stage II & III. 100 HIV+ve individuals between 18-50 y (71% males) were included in the study. 50 cases conformed to CDC stage II–Asymptomatic HIV infection, and 50 cases to CDC stage III–Persistent Generalised Lymphadenopathy (PGL). Cases were stratified according to their clinical status and CD4+ve lymphocyte counts. The randomisation charts were prepared much before the start of the trial by randomly assigning placebo and verum codes to registration numbers from 1 to 50. A single individualised homeopathic remedy was prescribed in each case and was followed up at intervals of 15 d to one month. A six months study was performed for each registered case. Assessment of progress was made by evaluation of CD+ve lymphocyte counts, which was the prospectively-defined main outcome measure of the study; the results were compared with the base line immune status.
RESULTS: In PGL, a statistically significant difference was observed in CD+ve T-lymphocyte counts between pre and post trial levels in verum group (P < 0.01). In the placebo group a similar comparison yielded non-significant results. (P = 0.91). Analysis of change in the pre and post trial counts of CD4+ve cells between groups was also statistically significant (P = 0.04). In asymptomatic HIV infection, differences in absolute CD4+ve lymphocyte counts between pre and post trial levels were not significant. Analysis of changes in pre and post trial CD4 levels of placebo and verum groups for combined strata of asymptomatic and PGL groups was also not significant.
CONCLUSION: The study suggests a possible role of homeopathic treatment in HIV infection in symptomatic phase, as evidenced by a statistically significant elevation of base line immune status in persistent generalised lymphadenopathy.
Introduction: Identifying the need for strengthening of the immune system, the investigator has developed new Human Immunodeficiency Virus (HIV) nosode and evaluated its effect on HIV positive individuals through a clinical trial.
Methods: Standardized and the scientific method of HIV nosode preparation has been described and documented. Thirty-seven HIV-infected persons were registered for the trial, and ten participants were dropped out from the study, so the effect of HIV nosode 30C and 50C, was concluded on 27 participants under the trial.
Results: Out of 27 participants, 7 (25.93%) showed a sustained reduction in the viral load from 12 to 24 weeks. Similarly 9 participants (33.33%) showed an increase in the CD4+ count by 20% altogether in 12 th and 24 th week. Significant weight gain was observed at week 12 (P = 0.0206). 63% and 55% showed an overall increase in either appetite or weight. The viral load increased from baseline to 24 week through 12 week in which the increase was not statistically significant (P > 0.05). 52% (14 of 27) participants have shown either stability or improvement in CD4% at the end of 24 weeks, of which 37% participants have shown improvement (1.54-48.35%) in CD4+ count and 15% had stable CD4+ percentage count until week 24 week. 16 out of 27 participants had a decrease (1.8-46.43%) in CD8 count. None of the adverse events led to discontinuation of study.
Conclusion: The study results revealed improvement in immunological parameters, treatment satisfaction, reported by an increase in weight, relief in symptoms, and an improvement in health status, which opens up possibilities for future studies.
Case Examples of the Successful Homeopathic Treatment of HIV/AIDS:
Three cases of HIV/AIDS: Felician, Esther, and Mary by Jeremy Sherr
A Day in the Clinic by Camilla Sherr
Case Examples Homeopathy for Health in Africa